AGP Executive Report
Last update: 2 hours agoWorkplace Safety: A 26-year-old foreign subcontractor was crushed to death at HD Hyundai’s Ulsan shipyard, the fourth fatal incident at company sites this year, prompting police and the Occupational Safety and Health Agency to investigate and issue a partial stop-work order while a union alleges unsafe conditions and pressure to work faster. Biopharma Dealmaking: Samsung Biologics announced an all-cash $1.8B takeover of Switzerland’s PolyPeptide Group AG to expand into peptide manufacturing and strengthen its multi-modality CDMO platform, with completion targeted by end-2026. Clinical Research & Trials: Kolon’s phase 3 cell-based gene therapy for knee osteoarthritis missed co-primary endpoints in a U.S. trial, shifting attention to another late-stage study expected to report in October. Market Mood for Health Tech: South Korea’s chip-heavy KOSPI slid sharply as Middle East tensions pushed oil above $90, adding pressure to global markets that can affect funding and supply chains for healthcare innovation. Public Health & Access: A federal judge temporarily blocked South Dakota from enforcing an anti-abortion advertising law against Mayday Health, keeping online information about abortion pills accessible—for now.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
